for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NanoString Technologies Inc

NSTG.OQ

Latest Trade

26.34USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.27

 - 

34.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.34
Open
--
Volume
--
3M AVG Volume
8.82
Today's High
--
Today's Low
--
52 Week High
34.69
52 Week Low
13.27
Shares Out (MIL)
35.74
Market Cap (MIL)
953.49
Forward P/E
-10.72
Dividend (Yield %)
--

Next Event

Q4 2019 NanoString Technologies Inc Earnings Release

Latest Developments

More

NanoString Technologies Releases Third Quarter Results

Nikko Asset Management Americas Reports 11.02% Passive Stake In Nanostring Technologies As Of Sept 30

Nanostring Technologies Reports Q2 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NanoString Technologies Inc

NanoString Technologies, Inc. develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company's nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Company markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use.

Industry

Biotechnology & Drugs

Contact Info

530 Fairview Ave N

+1.206.3786266

https://www.nanostring.com

Executive Leadership

William D. Young

Independent Chairman of the Board

R. Bradley Gray

President, Chief Executive Officer, Director

K. Thomas Bailey

Chief Financial Officer, Treasurer

John Chad Brown

Senior Vice President - Sales and Marketing

Mary Tedd Allen

Senior Vice President - Operations and Administration

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-2.340

2017

-1.840

2018

-2.780

2019(E)

-2.488
Price To Earnings (TTM)
--
Price To Sales (TTM)
8.03
Price To Book (MRQ)
13.13
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
109.10
LT Debt To Equity (MRQ)
109.10
Return on Investment (TTM)
-57.76
Return on Equity (TTM)
-46.11

Latest News

Latest News

BRIEF-Nanostring Technologies Q1 Loss Per Share $0.75

* NANOSTRING TECHNOLOGIES RELEASES OPERATING RESULTS FOR FIRST QUARTER OF 2018

BRIEF-Nanostring Technologies Reports Q4 Loss Per Share $0.34

* NANOSTRING TECHNOLOGIES RELEASES FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND PROVIDES 2018 OUTLOOK

BRIEF-Nanostring Technologies Q4 Loss Per Share $0.34

* NANOSTRING TECHNOLOGIES RELEASES FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND PROVIDES 2018 OUTLOOK

BRIEF-Nanostring Appoints Thomas Bailey As CFO

* NANOSTRING APPOINTS THOMAS BAILEY AS CHIEF FINANCIAL OFFICER

BRIEF-Nanostring Technologies Signs Sales Agreement With Cowen And Co

* NANOSTRING TECHNOLOGIES SIGNS SALES AGREEMENT WITH COWEN AND CO RELATING TO COMMON STOCK OFFERING OF UP TO $40 MILLION - SEC FILING Source text (http://bit.ly/2CPZkbR) Further company coverage:

BRIEF-NanoString And RikenGenesis Announce Partnership To Commercialize Ncounter-Based Diagnostic Assays In Japan

* NANOSTRING AND RIKENGENESIS ANNOUNCE PARTNERSHIP TO COMMERCIALIZE NCOUNTER-BASED DIAGNOSTIC ASSAYS IN JAPAN

BRIEF-Nanostring Technologies reports Q3 loss per share $0.45

* Nanostring Technologies Inc releases operating results for third quarter of 2017

BRIEF-‍Nanostring and NSABP Foundation enter into agreement to study immunophenotypes in colorectal cancer​

* Nanostring and NSABP foundation enter into agreement to study immunophenotypes in colorectal cancer Source text for Eikon: Further company coverage:

BRIEF-NanoString Technologies Inc files for mixed shelf of up to $100 million - SEC filing

* NanoString Technologies Inc files for mixed shelf of up to $100 million - SEC filing Source text: [http://bit.ly/2iIzVbn] Further company coverage:

BRIEF-NanoString Technologies Q2 loss per share $0.20

* NanoString Technologies releases operating results for second quarter of 2017

BRIEF-Nanostring Technologies signs‍ collaboration agreement with Lam Research

* Nanostring technologies- co, lam research announced collaboration to develop nanostring's proprietary hyb & seq next generation sequencing platform

BRIEF-Nanostring Technologies Inc says co entered into collaboration agreement with Lam Research Corporation- SEC Filing

* Nanostring Technologies Inc - on August 4, 2017, Nanostring Technologies, Inc. entered into collaboration agreement with lam research corporation

BRIEF-NanoString Technologies announces pricing of offering of 3 mln shares of common stock

* NanoString Technologies announces pricing of offering of 3,000,000 shares of common stock

BRIEF-NanoString announces offering of common stock

* Nanostring technologies- agreement to sell 2.75 million shares of common stock to robert w. Baird & co. Inc as underwriter in underwritten public offering Source text for Eikon: Further company coverage:

BRIEF-Nanostring appoints Elisha Finney to board of directors

* Nanostring appoints Elisha Finney to board of directors Source text for Eikon: Further company coverage:

BRIEF-Nanostring Technologies Q1 loss per share $0.87

* Nanostring Technologies releases operating results for first quarter of 2017

BRIEF-Nanostring Technologies Q4 loss per share $0.55

* Sees 2017 gross margin on product and service revenues in range of 57% to 58%

BRIEF-NanoString Technologies provides preliminary operational and financial results for 2016

* NanoString Technologies provides preliminary operational and financial results for 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up